BURLINGAME, Calif., July 6 /PRNewswire/ -- BioSeek, Inc., a leader in applying integrated human biology systems for developing new therapeutics, announced today that it has entered into a collaboration agreement with GlaxoSmithKline (GSK). Under the collaboration, BioSeek will apply its BioMAP(R) Systems for the characterization of compounds from GSK.
BioSeek's BioMAP(R) Systems are a series of human primary cell-based assay systems designed to replicate the intricate cell and pathway interactions present in human disease biology. Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP profiles) that can be compared to a large number of reference profiles in BioSeek's database. BioMAP profiling can provide in-depth characterization of drug function, including defining mechanism of action and secondary activities, and can provide insights into potential clinical applications.
"We are excited to be working closely with the innovative scientific teams in GSK as we continue to demonstrate the utility of BioMAP Systems to drive drug discovery," commented Peter Staple, chief executive officer of BioSeek. "This collaboration will enable us to make use of the full range of applications of our technology."
Financial terms of the agreement were not disclosed.
About BioSeek
BioSeek is improving the success rate of pharmaceutical research and development by integrating human biology from the early stages of drug discovery onward. The Company's BioMAP(R) Systems incorporate predictive human cell-based disease models that generate uniquely informative activity signatures for each potential drug, driving the selection and development of new drug candidates. BioSeek is leveraging BioMAP(R) Systems technology in collaborations to enhance the productivity of its pharmaceutical partners' pipelines, and in the Company's internal programs to identify promising compounds for proprietary development in the fields of inflammation, cardiovascular diseases, autoimmune diseases and related indications.
For more information, go to http://www.bioseekinc.com Contacts: BioSeek, Inc. Peter D. Staple, Chief Executive Officer Tel: 650.552.0751 E-mail: pstaple@bioseekinc.com MacDougall BioMedical Communications Kari Watson Tel: 508.647.0209 E-mail: kwatson@macbiocom.com
BioSeek, Inc.CONTACT: Peter D. Staple, Chief Executive Officer of BioSeek, Inc., +1-650-552-0751, pstaple@bioseekinc.com; or Kari Watson of MacDougallBioMedical Communications, +1-508-647-0209, kwatson@macbiocom.com
Web site: http://www.bioseekinc.com/
